Scarica l'app Stockscreener
21.29
5.00%
-1.12
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at The Goldman Sachs Group - Defense World
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Can This Novel Dual-Action IBD Treatment Transform Patient Care? New Data Reveals Promising Results - StockTitan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
1,955 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call - MSN
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect? - MSN
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call By Investing.com - Investing.com
Spyre (SYRE) Unveils Strategic Talent Retention Plan: 35K Options with 10-Year Window - StockTitan
China Universal Asset Management Co. Ltd. Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - cnhinews.com
A company insider recently sold 6,700 shares of Spyre Therapeutics Inc [SYRE]. Should You also Consider to Sale? - Knox Daily
Financial Analysis: Spyre Therapeutics Inc (SYRE)’s Ratios Unveil Key Insights - The Dwinnex
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Oruka Therapeutics initiated with an Outperform at Wolfe Research - MSN
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
JPMorgan Chase & Co. Has $867,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Assenagon Asset Management S.A. Has $527,000 Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Assenagon Asset Management S.A. Cuts Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $54.83 - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 9.4%Time to Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.3%What's Next? - MarketBeat
Lifesci Capital Has Positive Outlook of SYRE FY2024 Earnings - Defense World
FY2024 EPS Forecast for Spyre Therapeutics Lifted by Analyst - MarketBeat
Get Caught Trying - Audacy
Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Given "Outperform" Rating at Wedbush - MarketBeat
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts - PR Newswire
Spyre Therapeutics Unveils Ambitious 2025 Pipeline Plans with $600M Cash Runway Through 2028 - StockTitan
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 9.2%Here's Why - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Jane Street Group LLC - Defense World
Spyre Therapeutics Awards Key Employee Stock Options at $24.35 with 10-Year Term - StockTitan
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Price Target at $51.50 - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Geode Capital Management LLC Has $26.21 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Geode Capital Management LLC Purchases 125,214 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Contrasting Spyre Therapeutics (NASDAQ:SYRE) & Generation Bio (NASDAQ:GBIO) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 2.5%Here's Why - MarketBeat
Barclays PLC Buys 41,424 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Barclays PLC Boosts Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):